DE2710327C3 - Verwendung von Benzaldehyd - Google Patents

Verwendung von Benzaldehyd

Info

Publication number
DE2710327C3
DE2710327C3 DE2710327A DE2710327A DE2710327C3 DE 2710327 C3 DE2710327 C3 DE 2710327C3 DE 2710327 A DE2710327 A DE 2710327A DE 2710327 A DE2710327 A DE 2710327A DE 2710327 C3 DE2710327 C3 DE 2710327C3
Authority
DE
Germany
Prior art keywords
benzaldehyde
cells
test
effect
results
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2710327A
Other languages
German (de)
English (en)
Other versions
DE2710327B2 (de
DE2710327A1 (de
Inventor
Mutsuyuki Matsudo Chiba Kochi
Setsuo Tokio Takeuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIKEN
Original Assignee
RIKEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RIKEN filed Critical RIKEN
Publication of DE2710327A1 publication Critical patent/DE2710327A1/de
Publication of DE2710327B2 publication Critical patent/DE2710327B2/de
Application granted granted Critical
Publication of DE2710327C3 publication Critical patent/DE2710327C3/de
Expired legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE2710327A 1976-03-09 1977-03-09 Verwendung von Benzaldehyd Expired DE2710327C3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2522576A JPS52108027A (en) 1976-03-09 1976-03-09 Anticarcinogen

Publications (3)

Publication Number Publication Date
DE2710327A1 DE2710327A1 (de) 1977-09-15
DE2710327B2 DE2710327B2 (de) 1980-04-17
DE2710327C3 true DE2710327C3 (de) 1981-02-12

Family

ID=12160014

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2710327A Expired DE2710327C3 (de) 1976-03-09 1977-03-09 Verwendung von Benzaldehyd

Country Status (9)

Country Link
US (1) US4983636A (enExample)
JP (1) JPS52108027A (enExample)
AU (1) AU499475B2 (enExample)
BE (1) BE852283A (enExample)
CA (1) CA1093971A (enExample)
DE (1) DE2710327C3 (enExample)
FR (1) FR2343475A1 (enExample)
GB (1) GB1573965A (enExample)
NL (1) NL172917C (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5446001U (enExample) * 1977-09-07 1979-03-30
JPS5830032B2 (ja) * 1981-02-18 1983-06-27 呉羽化学工業株式会社 ビフイダス菌の増殖剤
JPS6112623A (ja) * 1984-06-28 1986-01-21 Kaken Pharmaceut Co Ltd エンケフアリナ−ゼ阻害剤
JPS6256423A (ja) * 1985-09-06 1987-03-12 Kaken Pharmaceut Co Ltd 悪液質治療改善剤
US4874780A (en) * 1987-03-11 1989-10-17 Norsk Hydro A.S. Anticancer compounds
AT393221B (de) * 1988-02-03 1991-09-10 Leopold Pharma Gmbh Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
JPH0269540A (ja) * 1988-09-05 1990-03-08 Chisso Corp 結晶性ポリオレフイン組成物
US5330744A (en) * 1988-11-14 1994-07-19 Sloan-Kettering Institute For Cancer Research Method for increasing sensitivity to chemically induced terminal differentiation
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
US5789189A (en) * 1993-09-24 1998-08-04 The Regents Of The University Of California Inhibition of cyst formation by cytoskeletal specific drugs
DE19508654B4 (de) * 1995-03-13 2006-08-10 Stepan Co., Northfield Tuberkulozides Desinfekionsmittel und dessen Verwendung
CN1378450A (zh) 1999-09-08 2002-11-06 斯隆-凯特林癌症研究院 新型细胞分化剂和组蛋白脱乙酰基酶抑制剂及其使用方法
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
WO2002078451A1 (en) * 2001-03-30 2002-10-10 Premier Botanicals Ltd. Pesticidal compositions from prunus
CA2520611A1 (en) * 2003-04-01 2004-10-21 Memorial Sloan-Kettering Cancer Center Hydroxamic acid compounds and methods of use thereof
JP6715007B2 (ja) * 2015-01-06 2020-07-01 Ｓｈｉｏｄａライフサイエンス株式会社 天然ベンズアルデヒド水の製造方法、該製造方法によって製造された天然ベンズアルデヒド水、及び、該天然ベンズアルデヒド水を含有する抗腫瘍剤
JP6898072B2 (ja) * 2015-08-27 2021-07-07 秀行 佐谷 １４−３−３タンパク質活性調節剤
JP7054085B2 (ja) * 2016-06-30 2022-04-13 Ｓｈｉｏｄａライフサイエンス株式会社 バラ科サクラ属に属する植物の葉の抽出液を含有する抗腫瘍剤
JP6541087B1 (ja) * 2018-10-16 2019-07-10 株式会社ワールドナッツ アーモンドペースト組成物
JP7018531B1 (ja) * 2021-04-30 2022-02-10 潤 齋藤 Ａｘｌ阻害剤
JP7796158B2 (ja) * 2024-03-25 2026-01-08 潤 齋藤 Ｌｉｎ２８ｂ阻害剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2827452A (en) * 1955-05-31 1958-03-18 Univ Minnesota Stabilization of materials

Also Published As

Publication number Publication date
FR2343475B1 (enExample) 1980-04-25
FR2343475A1 (fr) 1977-10-07
AU499475B2 (en) 1979-04-26
AU2307377A (en) 1978-09-14
CA1093971A (en) 1981-01-20
JPS54962B2 (enExample) 1979-01-18
DE2710327B2 (de) 1980-04-17
NL7702535A (nl) 1977-09-13
JPS52108027A (en) 1977-09-10
BE852283A (fr) 1977-09-09
GB1573965A (en) 1980-08-28
NL172917C (nl) 1983-11-16
NL172917B (nl) 1983-06-16
DE2710327A1 (de) 1977-09-15
US4983636A (en) 1991-01-08

Similar Documents

Publication Publication Date Title
DE2710327C3 (de) Verwendung von Benzaldehyd
Simon et al. Screening trial with the coordinated gold compound auranofin using mouse lymphocytic leukemia P388
DE69927125T2 (de) Zusammensetzung gegen Erhöhung oder zur Herabsetzung des Blutzuckerspiegels
AT401470B (de) Pharmazeutische verwendung von 17-ketosteroiden
DE60019435T2 (de) Therapeutische anwendung von polymere die gamma-hydroxybutyrat enthalten
DE69031033T2 (de) Verwendung von eicosapentaensäure zur behandlung der kachexie
DE3784905T2 (de) Gamma-l-glutamyl-l-cysteinethylester und arzneimittel, die dieses als aktives mittel enthalten.
DE60006810T2 (de) Dicarboxylato-diamin-platin-derivate und zusammensetzungen die diese als antitumormittel enthalten
DE69023442T2 (de) Verwendung einer Cyaninfarbe in einem antitumoralen Mittel.
DE69104362T2 (de) Autobiotika sowie deren verwendung bei der in vivo eliminierung körperfremder zellen.
DE3511609C2 (enExample)
DE3786304T2 (de) Immunostimulierende Arzneimittel.
WO1991002529A2 (en) Product and method for killing abnormal vertebrate cells
CH654212A5 (de) Zubereitung zur steigerung der therapeutischen wirkung eines antitumormittels und diese zubereitung enthaltende antitumor-zubereitung.
EP0305743B1 (de) Pharmazeutisches Kombinationspräparat sowie dessen Herstellung und Verwendung
DE69213757T2 (de) Verwendung von kreatinphosphat oder phosphoenolbrenztraubensäure zur behandlung von tumoren
DE3115080A1 (de) Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung
DE3638124A1 (de) Neue pharmazeutische verwendung von ebselen
EP0817623B1 (de) Arzneistoffe zur selektiven bekämpfung von tumorgewebe
EP2908829A1 (de) Anthocyanidin-komplex zur behandlung von multiplem myelom
DE2546001C3 (de) Immunostimulierende, Phospholipide enthaltende Stoffgemische, diese Stoffgemische enthaltende Arzneimittel und Verfahren zu ihrer Gewinnung
DE2243777C3 (de) Verwendung von Bis-(2,2,4-Trimethyl-1,2-dihydrochinol-6-yl)-methan bei der strahlensensibilisierenden Tumorhemmung
KR960015953B1 (ko) 피부에 축적하는 외용의 항바이러스성 약학적 조성물 및 그 제조방법
US4892876A (en) Method for inhibiting HIV and an pharmaceutical composition therefor
EP0194571B1 (de) Heterocyclische Disulfide, Verfahren zu ihrer Herstellung und pharmazeutische Mittel, die diese Verbindungen enthalten

Legal Events

Date Code Title Description
C3 Grant after two publication steps (3rd publication)
8380 Miscellaneous part iii

Free format text: ES ERFOLGT EIN ERGAENZUNGSDRUCK DER FEHLENDEN ZEICHNUNGEN

8339 Ceased/non-payment of the annual fee